PharmaCorp Rx (PCRX) Q1 2025 earnings summary

Executive summary

• Achieved first quarter of positive net income, reporting $254,000 for Q1 2025.

• Same-store sales increased 4.0% year-over-year, indicating organic growth.

• Prescription volumes rose 3.2% year-over-year, reflecting sustained patient engagement.

• Entered non-binding letters of intent to acquire four pharmacies for $12.5 million, supporting acquisition-driven growth.

Financial highlights

• Net income reached $254,000 for Q1 2025, marking a significant milestone.

• Same-store sales up 4.0% year-over-year; prescription count up 3.2% year-over-year.

• Q1 results modestly affected by Easter holiday timing, with some seasonal revenue shifting to Q2.

Outlook and guidance

• Expects momentum from Q1 results to continue in future quarters.

• Anticipates normalization of seasonal revenue effects over the first half of the year.

• Remains committed to expanding national footprint through acquisitions and operational excellence.